View in EDS HTML Full Text PDF Full Text

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age.

Saved in:
Bibliographic Details
Title: Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age.
Authors: Poder A; Tartu University Hospital, 50406 Tartu, Estonia., Oberije J; CSL Seqirus, 1105 BJ Amsterdam, The Netherlands., Meyer J; Velocity Clinical Research, Lincoln, NE 68510, USA., Heymer P; Klinische Forschung Dresden GmbH, 01069 Dresden, Germany., Molrine D; CSL Seqirus, Waltham, MA 02451, USA., Versage E; CSL Seqirus, Waltham, MA 02451, USA., Isakov L; CSL Seqirus, Waltham, MA 02451, USA., Zhang Q; CSL Seqirus, Summit, NJ 07901, USA., Hohenboken M; CSL Seqirus, Waltham, MA 02451, USA.
Source: Vaccines [Vaccines (Basel)] 2023 Sep 26; Vol. 11 (10). Date of Electronic Publication: 2023 Sep 26.
Publication Type: Journal Article
Journal Info: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37896932
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Poder+A%22">Poder A</searchLink>; Tartu University Hospital, 50406 Tartu, Estonia.<br /><searchLink fieldCode="AU" term="%22Oberije+J%22">Oberije J</searchLink>; CSL Seqirus, 1105 BJ Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Meyer+J%22">Meyer J</searchLink>; Velocity Clinical Research, Lincoln, NE 68510, USA.<br /><searchLink fieldCode="AU" term="%22Heymer+P%22">Heymer P</searchLink>; Klinische Forschung Dresden GmbH, 01069 Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Molrine+D%22">Molrine D</searchLink>; CSL Seqirus, Waltham, MA 02451, USA.<br /><searchLink fieldCode="AU" term="%22Versage+E%22">Versage E</searchLink>; CSL Seqirus, Waltham, MA 02451, USA.<br /><searchLink fieldCode="AU" term="%22Isakov+L%22">Isakov L</searchLink>; CSL Seqirus, Waltham, MA 02451, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+Q%22">Zhang Q</searchLink>; CSL Seqirus, Summit, NJ 07901, USA.<br /><searchLink fieldCode="AU" term="%22Hohenboken+M%22">Hohenboken M</searchLink>; CSL Seqirus, Waltham, MA 02451, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101629355%22">Vaccines</searchLink> [Vaccines (Basel)] 2023 Sep 26; Vol. 11 (10). <i>Date of Electronic Publication: </i>2023 Sep 26.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22MDPI+AG%22">MDPI AG </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101629355 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2076-393X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222076393X%22">2076393X </searchLink><i>NLM ISO Abbreviation: </i>Vaccines (Basel) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37896932
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/vaccines11101528
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Poder A
      – PersonEntity:
          Name:
            NameFull: Oberije J
      – PersonEntity:
          Name:
            NameFull: Meyer J
      – PersonEntity:
          Name:
            NameFull: Heymer P
      – PersonEntity:
          Name:
            NameFull: Molrine D
      – PersonEntity:
          Name:
            NameFull: Versage E
      – PersonEntity:
          Name:
            NameFull: Isakov L
      – PersonEntity:
          Name:
            NameFull: Zhang Q
      – PersonEntity:
          Name:
            NameFull: Hohenboken M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 26
              M: 09
              Text: 2023 Sep 26
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 2076-393X
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Vaccines
              Type: main
ResultId 1